Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More Deal Of The Year Nominees

Executive Summary

It's time for The IN VIVO Blog's Third Annual Deal of the Year competition. This year, awards will be presented in three categories to highlight the most interesting and creative deal making solutions of 2010.

You may also be interested in...



As Pfizer And UCSF Tighten Ties, More Deals With Academia Could Follow

Pfizer Inc.’s latest pledge to academic research, a five-year $85 million agreement to fund projects at the University of California, San Francisco, isn’t just a deepening of the Big Pharma’s commitment to on-campus studies intended to bridge the so-called Valley of Death between the laboratory and the commercial sector. It’s also a sign of the increased importance of deals between pharmas and universities, which give commercial partners access to new research earlier in the development process while nudging academics toward projects with commercial relevance in mind.

King of Pain: Pfizer's Move into Abuse Resistant Opioids and the Virtues of Massive Scale

Pfizer’s $3.3 billion acquisition of King eliminates the primary opportunity for investors to play in the abuse-resistant formulation space and renewed questions about the logic of perpetual expansion atop Big Pharma. But the realities of the abuse resistant marketplace suggest it makes a good case for scale and diversity. Is this a sign of things to come in other drug classes?

Deals Of The Week: Sanofi, Teva, Ablexis; Kadmon Emerges From Stealth Mode

Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052963

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel